Global Oncology Innovation Continues Despite Pandemic; Global R&D Pipeline Reached 3,500 New Drugs in 2020, up 75% from 2015,...
June 03 2021 - 4:30PM
Business Wire
- 17 new cancer medicines launched in the U.S. in 2020, bringing
the total over the past 5 years to 62 innovative therapies,
collectively approved for 130 indications across 24 different tumor
types
- The pandemic continues to have a substantial impact on cancer
care with oncologists in the US, Japan and Europe reporting
caseloads that are 26% to 51% lower than pre-pandemic levels
- Check-point inhibitors first introduced in 2011 have induced
responses in some previously intractable cancers and have seen
remarkable uptake, almost doubling since 2018 in use per capita in
the U.S., higher than EU4, UK and Japan.
- Access to medicines has been steadily increasing and 9.2
billion Defined Daily Doses (DDDs) were delivered globally in 2020
but variability across countries remains high
- Global spending on oncology drugs – using list or invoice
prices – reached $164 billion in 2020; a compound annual growth
rate of 14.3% over the past 5 years
Despite the substantial impact of the COVID-19 pandemic on
patient care during 2020, the scientific advances in oncology
continued, with 3,500 new drugs in the pipeline in 2020, up 75
percent since 2015. Oncologists worldwide report caseloads that are
26 to 51 percent lower than pre-pandemic levels, resulting in
delays in necessary treatments. Despite this, the surge in
innovative cancer medicines continued, as reflected in clinical
trial activity, the robust pipeline of new treatments in
development, and the increased use of available therapeutics by
more patients.
“While the pandemic still is having significant impact on cancer
care, innovations in oncology continues largely unaffected,
reflecting the substantial and sustained commitment to advancing
care for patients by oncologists and other care providers,
governments and payers, and life sciences companies,” said Murray
Aitken, executive director of the IQVIA Institute for Human Data
Science. “The continued surge in new innovative cancer medicines
demonstrates the remarkable capacity and ingenuity of the global
oncology community in a very challenging environment.”
A few key highlights of the IQVIA Institute Global Oncology
Report include:
- Impact of COVID-19 on Cancer Care: The pandemic
continues to have a substantial impact on cancer care with
oncologists in the U.S., Japan and Europe reporting caseloads that
are 26 to 51 percent lower than pre-pandemic levels, delays in
necessary treatments, screenings at 11 to 23 percent below baseline
levels and community oncologists in the U.S. reporting an
increasing share of their new patients presenting with metastatic
cancer
- Innovation: The surge of new innovative cancer medicines
that began a decade ago continued in 2020 with 17 new drugs being
launched and made available – at different times - to patients
around the world, especially those with rare cancers
- Research and Development: Scientific breakthroughs in
understanding rare cancers that lead to novel therapeutics, and a
biomedical eco-system that provides funding and support for R&D
especially among emerging biopharma companies, have resulted in a
pipeline of almost 3,500 potential cancer treatments, up 75 percent
since 2015
- Bringing Scientific Advances to Cancer Patients: Access
to medicines has been steadily increasing and 9.2 billion DDDs were
delivered globally in 2020, but variability across countries
remains high. The use of predictive biomarkers to effectively
deliver precision medicines to those who will benefit from them
remains variable across cancer types and countries
- Spending on Oncology Medicines: The surge in innovation
treatments in recent years, strong focus across health systems to
increase early diagnosis and expand patient access to treatments,
has resulted in global spending on oncology drugs of $164 billion
in 2020, growing to an estimated $269 billion by 2025
The full version of the report, including a detailed description
of the methodology, is available at www.IQVIAInstitute.org. The
study was produced independently as a public service, without
industry or government funding.
About the IQVIA Institute for Human Data Science
The IQVIA Institute for Human Data Science contributes to the
advancement of human health globally through timely research,
insightful analysis and scientific expertise applied to granular
non-identified patient-level data.
Fulfilling an essential need within healthcare, the Institute
delivers objective, relevant insights and research that accelerate
understanding and innovation critical to sound decision making and
improved human outcomes. With access to IQVIA’s institutional
knowledge, advanced analytics, technology and unparalleled data,
the Institute works in tandem with a broad set of healthcare
stakeholders to drive a research agenda focused on Human Data
Science, including government agencies, academic institutions, the
life sciences industry, and payers. More information about the
IQVIA Institute can be found at www.IQVIAInstitute.org.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 72,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors, and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210603006037/en/
Nick Childs, IQVIA Investor Relations
(nicholas.childs@iqvia.com) +1.973.316.3828
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
IQVIA (NYSE:IQV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2023 to Sep 2024